Scarica l'app Stockscreener
0.3384
2.39%
0.0079
Dopo l'orario di chiusura:
.35
0.0116
+3.43%
Ovid Therapeutics Inc Borsa (OVID) Ultime notizie
Balance Sheet Insights: Ovid Therapeutics Inc (OVID)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Ovid Therapeutics Inc (OVID) Stock: The Story of a 52-Week Stock Range - investchronicle.com
Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier - insights.citeline.com
Transcript : Ovid Therapeutics Inc.Special Call - marketscreener.com
Ovid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results - mx.advfn.com
Ovid Therapeutics (OVID) to Showcase Biomarker Advances in Epile - GuruFocus
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 | OVID Stock News - GuruFocus
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025 - GlobeNewswire
Harvard Expert to Present Breakthrough Epilepsy Treatment Data at Ovid Therapeutics Event - Stock Titan
Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Sold by BNP Paribas Financial Markets - Defense World
HC Wainwright Predicts Weaker Earnings for Ovid Therapeutics - Defense World
Ovid Therapeutics (NASDAQ:OVID) Price Target Cut to $1.50 by Analysts at HC Wainwright - Defense World
Ovid Therapeutics Reports Q1 2025 Financial Results - TipRanks
Ovid Therapeutics (OVID): HC Wainwright & Co. Lowers Price Targe - GuruFocus
Ovid Therapeutics (OVID): Price Target Revised Amid Future Growt - GuruFocus
Ovid Therapeutics (OVID): Price Target Revised Amid Future Growth Prospects | OVID Stock News - GuruFocus
H.C. Wainwright cuts Ovid stock price target to $1.50, keeps buy rating - Investing.com
Brokerages Set Ovid Therapeutics Inc. (NASDAQ:OVID) PT at $3.03 - Defense World
What is B. Riley’s Forecast for OVID Q2 Earnings? - Defense World
Q3 EPS Estimate for Ovid Therapeutics Raised by Analyst - Defense World
Wedbush Decreases Earnings Estimates for Ovid Therapeutics - Defense World
Analysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Ovid Therapeutics (OVID) - The Globe and Mail
Ovid Therapeutics (OVID) Exceeds Q1 Revenue Expectations and Adv - GuruFocus
Ovid Therapeutics (OVID) Reports $43 Million in Cash Reserves | - GuruFocus
Ovid Therapeutics Reports Business Updates and First Quarter 202 - GuruFocus
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Ovid Therapeutics Inc Reports Q1 2025 EPS of -$0.14, Meeting Est - GuruFocus
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results | OVID Stock News - GuruFocus
Ovid Therapeutics (OVID) Reports $43 Million in Cash Reserves | OVID Stock News - GuruFocus
Ovid Therapeutics Inc. SEC 10-Q Report - TradingView
Ovid Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Ovid Therapeutics (OVID) Projected to Post Quarterly Earnings on Tuesday - Defense World
Ovid Therapeutics Inc. (NASDAQ:OVID) Shares Purchased by Renaissance Technologies LLC - Defense World
Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results - ADVFN
Dup15q syndrome Market: Epidemiology, Therapies, Companies, - openPR.com
JPMorgan Chase & Co. Decreases Stock Holdings in Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World
Ovid Therapeutics (NASDAQ:OVID) Upgraded at William Blair - Defense World
Analysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Target Price at $3.03 - Defense World
Ovid Therapeutics Inc [OVID] stock for 2,956 USD was sold by ALEXANDER MARGARET A. - knoxdaily.com
The OVID Stock Puzzle: Unraveling Ovid Therapeutics Inc’s Fluctuating Performance - investchronicle.com
A closer look at Ovid Therapeutics Inc (OVID) is warranted - uspostnews.com
Ovid Therapeutics to Present at the 12th International Epilepsy Colloquium | Libero Quotidiano.it - Libero Quotidiano
Dravet Syndrome Treatment Market Future Business - openPR.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Ovid Therapeutics stock hits 52-week low at $0.27 By Investing.com - Investing.com South Africa
Ovid Therapeutics stock hits 52-week low at $0.27 - Investing.com
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):